中国川崎病巨大冠状动脉瘤患儿利伐沙班校准抗Xa活性参考范围:群体药动学与药效学分析
该研究基于35例中国川崎病合并巨大冠状动脉瘤患儿的前瞻性稀疏采样数据,采用NONMEM建立利伐沙班群体PK/PD模型,描述利伐沙班浓度与抗Xa活性的线性关系,并基于全部应答良好患儿的抗Xa活性提出峰浓度和谷浓度参考范围,以平衡疗效与安全性。
要点
- 利伐沙班浓度与抗Xa活性呈线性关系:抗Xa=0.945×Criva+4.37。
- 推荐峰浓度(末次给药后2-4h)抗Xa活性范围50.9-187.3 ng/mL。
- 推荐谷浓度(末次给药后22-24h)抗Xa活性范围5.8-24.1 ng/mL。
核心结论
- 所建立的群体PK/PD模型可同时描述利伐沙班浓度与抗Xa活性。
- 推荐抗Xa活性范围可为中国川崎病合并巨大冠状动脉瘤患儿双联抗栓治疗中利伐沙班的使用提供参考。
研究设计与样本
- 基于前瞻性观察研究的前期人群,采用稀疏采样收集利伐沙班浓度与抗Xa活性数据。
- 使用NONMEM按PPP&D建模方法序贯建立群体PK/PD模型,共纳入35例患儿、145个利伐沙班浓度和85个抗Xa活性测量值。
主要发现
- 二房室模型加一阶消除最佳描述利伐沙班PK数据。
- 线性模型(抗Xa=0.945×Criva+4.37)用于描述利伐沙班浓度(0.5-500 ng/mL范围内)与抗Xa活性的关系。
- 全部患儿对临床所用剂量方案应答良好,其抗Xa活性被视为平衡疗效与安全性的参考范围。
关键数值与推荐
- 推荐峰浓度(末次给药后2-4h)抗Xa活性范围为50.9-187.3 ng/mL。
- 推荐谷浓度(末次给药后22-24h)抗Xa活性范围为5.8-24.1 ng/mL。
临床怎么用
- 临床可参考所推荐的峰、谷抗Xa活性范围,在双联抗栓治疗下监测中国川崎病合并巨大冠状动脉瘤患儿利伐沙班的暴露。
- 可利用所建立的PK/PD模型和贝叶斯方法估算个体抗Xa活性动力学曲线。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to characterize the pharmacokinetics of rivaroxaban and its correlation with anti-Xa activity and recommend reference range of anti-Xa activity in Chinese children with giant coronary artery aneurysm (GCAA) after Kawasaki disease (KD). METHODS: Sparse sampling rivaroxaban concentration (Criva) and anti-Xa activity data from a prospective observational study conducted in the preceding population were analysed using NONMEM. The pharmacokinetic-pharmacodynamic (PK/PD) model was developed sequentially following a PPP&D modelling approach. The patients' kinetic profiles of anti-Xa activity were estimated by a Bayesian approach based on individual PK/PD parameters. Echocardiograms, coronary artery angiograms and clinical symptom evaluations were used to assess the effectiveness and safety of the clinically used dose regimen. RESULTS: This study included 35 children, with 145 rivaroxaban concentrations and 85 anti-Xa measurements collected. A two-compartment model with first-order elimination best described the PK data. A linear model (Anti-Xa = 0.945 × Criva + 4.37) was chosen to describe the relationship between Criva (within 0.5-500 ng/mL) and anti-Xa activity. Anti-Xa activity of patients, who all responded well to the medication, was regarded as the reference range for balancing the therapeutic effect and safety in Chinese paediatrics with GCAA after KD. The recommended anti-Xa activity range is 50.9-187.3 ng/mL at peak (2-4 h after last dose), and 5.8-24.1 ng/mL at trough (22-24 h after last dose). CONCLUSIONS: The developed population PK/PD model could be used to describe Criva and anti-Xa activity simultaneously. The recommended anti-Xa range could inform rivaroxaban use in Chinese children with GCAA after KD under dual antithrombotic therapy.
引用
- Liu B, Dai GA, Xu N, et al. Reference range of rivaroxaban-calibrated anti-Xa activity in Chinese children with giant coronary artery aneurysms after KawasakI disease: insights from a population pharmacokinetic and pharmacodynamic analysis. Br J Clin Pharmacol. 2025. PMID: 41222295. doi:10.1002/bcp.70324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。